Status:
UNKNOWN
Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning
Lead Sponsor:
Dr Kundan Singh Chufal
Conditions:
Esophageal Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
In esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy (NA-CCRT) followed by surgery is the current standard of care and ample evidence has accumulated supporting the view that complete pa...
Eligibility Criteria
Inclusion
- ECOG Performance Status: 0-2
- Patients with histopathological or cytopathological confirmed malignancy of the esophagus
- Histology: Squamous Cell Carcinoma and Adenocarcinoma
- Patients should have received NeoAdjuvant Concurrent Chemoradiation (NACCRT) followed by Surgery
- All therapeutic interventions (Radiotherapy, Chemotherapy \& Surgery) delivered within participating institutions
- At least one pre-NACCRT DICOM imaging dataset (HRCT/ 18-FDG PET-CT/ Radiotherapy planning CT) for each patient
Exclusion
- Patients with any metallic implants in the region of interest
- Patient with locally advanced disease or metastatic disease (T4 disease, Fistula, metastases)
- Patients with prior history of radiotherapy in the same region
- Patients developing a second malignancy in the esophagus
Key Trial Info
Start Date :
January 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04489368
Start Date
January 16 2020
End Date
July 1 2023
Last Update
December 28 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Illawarra Cancer Care Centre
Wollongong, Australia, 2500
2
Rajiv Gandhi Cancer Institute & Research Center
New Delhi, National Capital Territory of Delhi, India, 110019